Wegovy vs. Ozempic: same ingredient, different approved uses

Wegovy and Ozempic contain semaglutide, but their approved uses and product instructions are not identical. Compare the named products and their uses in MedlinePlus semaglutide injection and NIDDK prescription weight-management medicines. Clinical similarity between Wegovy and Ozempic does not make their instructions interchangeable. Ask why Wegovy or Ozempic fits the documented diagnosis.

MedlinePlus distinguishes semaglutide products by the health problem being treated. NIDDK identifies Wegovy in weight management and Ozempic as a diabetes product under a different name and use. A person asking about obesity alone should not assume the diabetes brand is the indicated product. Cardiovascular and other labeled uses have also changed over time, so the current prescribing information matters more than an old comparison chart. FDA warns about unapproved GLP-1 products marketed as substitutes for approved medicines. See FDA concerns with unapproved GLP-1 drugs. Evidence for Wegovy cannot automatically establish a result with Ozempic.

The most important practical issue is matching the labeled product to the diagnosis and insurance benefit. Patients with type 2 diabetes may have different therapeutic priorities from someone seeking obesity care. A formulary may also treat the two brands differently, and the device instructions are product-specific. A clinician can explain when an off-label use is considered and what follow-up is required. Check the specific warnings and patient instructions in MedlinePlus semaglutide injection and NIDDK prescription weight-management medicines. Let the prescriber direct any change from Wegovy to Ozempic; follow the dispensed package.

Ask whether the prescription is for weight management, glycemic control or another specific labeled purpose. Confirm that the pharmacy will dispense the named product, and ask what happens if coverage changes. For Wegovy or Ozempic, confirm the pharmacy, coverage and reassessment date. For a compounded form of Wegovy, request the medical rationale and directly applicable evidence.

A patient with obesity but no diabetes should ask why a diabetes-branded product is being proposed, and whether the current Wegovy indication applies. A patient with type 2 diabetes needs a discussion of glucose goals as well as weight. If an insurer denies one brand, that administrative decision does not make the other brand clinically equivalent. Write down the product name on the prescription rather than “semaglutide” alone. The branded instructions are not a reusable recipe for a compounded preparation. Ask how the care team would handle a pharmacy substitution request, a coverage denial or a new labeled use that is relevant to your diagnosis.